LUND, Sweden, Nov. 6, 2019 /PRNewswire/ -- Alligator
Bioscience (Nasdaq Stockholm: ATORX), today announced that the
company will present new preclinical data showing that their drug
candidate ATOR-1017 can induce a long-lasting immunological memory
which is of great importance in a potential future patient setting.
The results will be presented at the ongoing Society for
Immunotherapy of Cancer (SITC) 34th Annual Meeting. The ATOR-1017
drug candidate is in development for the treatment of metastasized
cancer.
Furthermore, the results show that treatment with ATOR-1017
activates the immune system in the tumor area but not systemically.
These preclinical data support a tumor-directed activity of
ATOR-1017. The aim is to focus the immune attack towards the tumor
in order to increase efficacy and minimize side effects for the
patient. ATOR-1017 is currently about to initiate Phase I clinical
study and dosing of the first patient is expected shortly.
"These preclinical data support the potential of ATOR-1017 to
generate a strong and long-lasting immune response or even to
induce immunity to cancer. This is our fourth asset to enter the
clinic and with its unique tumor-directed profile, we continue to
build a clinical pipeline of the next generation cancer
immunotherapies", said Per Norlén, CEO of Alligator Bioscience.
The upcoming Phase I study will be a first-in-human, dose
escalation study in patients with advanced cancer. It will be
conducted at three sites in Sweden
and will enroll up to 50 patients. The primary objective of the
study is to assess the safety and tolerability of ATOR-1017 and to
determine the recommended dose for the subsequent Phase II
studies.
Karin Enell Smith, Senior
Scientist at Alligator Bioscience will present a poster with the
title "ATOR-1017, a 4-1BB antibody developed for tumor-directed
immunotherapy of cancer" on Saturday
November 9 at the SITC 34th Annual Meeting held in National
Harbor, Maryland, US. The poster
presentation will be available on the Alligator web site
www.alligatorbioscience.com on the day of the presentation.
For further information, please contact:
Cecilia Hofvander, Director Investor
Relations & Communications
Phone +46 46 540 82 06
E-mail: cecilia.hofvander@alligatorbioscience.com
The information was submitted for publication, through the
agency of the contact person set out above, at 2:00 p.m. CET on November
6, 2019.
About ATOR-1017
ATOR-1017 is an immunostimulatory IgG4 antibody that activates
tumor-specific T cells and NK cells through the costimulatory
receptor 4-1BB. T cells and NK cells have the capacity to detect
and kill tumor cells, making 4-1BB a particularly attractive target
for cancer immunotherapy. ATOR-1017 has a unique profile related to
the fact that its immunostimulatory function is stronger in areas
where immune cells are abundant, notably in tumors. This creates an
opportunity for a strong immune activation, while minimizing side
effects for the patient.
About Alligator Bioscience
Alligator Bioscience AB is a clinical-stage biotechnology company
developing tumor-directed immuno-oncology antibody drugs.
Alligator's growing pipeline includes six lead clinical and
preclinical drug candidates: mitazalimab (ADC-1013), ATOR-1015,
ATOR-1017, ALG.APV-527 (co-developed with Aptevo Therapeutics
Inc.), ATOR-1144 and AC101 (in clinical development by Shanghai
Henlius Biotech Inc.). Alligator's shares are listed on Nasdaq
Stockholm (ATORX). The Company is headquartered in Lund, Sweden, and has approximately 55
employees. For more information, please visit
www.alligatorbioscience.com.
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/alligator-bioscience/r/alligator-bioscience-ator-1017-induces-long-lasting-immunity---new-preclinical-data-to-be-presented-,c2955229
The following files are available for download:
https://mb.cision.com/Main/12681/2955229/1136714.pdf
|
ATOR-1017 Induces
Long-Lasting Immunity â€" New Preclinical Data to be presented at
SITC 34th Annual Meeting
|